Symbols / SNTI Stock $0.86 +5.81% Senti Biosciences, Inc.

Healthcare • Biotechnology • United States • NCM
SNTI (Stock) Chart
About

Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company's product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma. In addition, it develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to gene therapies for tissue-directed targets, as well as partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 26.76M
Enterprise Value 37.45M Income -61.44M Sales 22.00K
Book/sh 0.18 Cash/sh 0.54 Dividend Yield —
Payout 0.00% Employees — IPO —
P/E — Forward P/E -0.96 PEG —
P/S 1216.33 P/B 4.75 P/C —
EV/EBITDA -0.69 EV/Sales 1702.06 Quick Ratio 1.31
Current Ratio 1.67 Debt/Eq 516.93 LT Debt/Eq —
EPS (ttm) -2.73 EPS next Y -0.90 EPS Growth —
Revenue Growth — Earnings 2026-03-27 08:00 ROA -48.89%
ROE -218.08% ROIC — Gross Margin 0.00%
Oper. Margin -370.95% Profit Margin 0.00% Shs Outstand 31.14M
Shs Float 11.52M Short Float 2.88% Short Ratio 6.21
Short Interest — 52W High 5.10 52W Low 0.77
Beta 2.13 Avg Volume 192.50K Volume 103.34K
Target Price $11.00 Recom Strong_buy Prev Close $0.81
Price $0.86 Change 5.81%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$11.00
Mean price target
2. Current target
$0.85
Latest analyst target
3. DCF / Fair value
$-13.49
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.85
Low
$6.00
High
$15.00
Mean
$11.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-30 main Chardan Capital Buy → Buy $11
2025-12-09 main Chardan Capital Buy → Buy $13
2025-11-21 init Leerink Partners — → Outperform $6
2025-10-14 init HC Wainwright & Co. — → Buy $12
2025-08-08 main Chardan Capital Buy → Buy $12
2025-06-12 main Chardan Capital Buy → Buy $12
2025-06-06 init Laidlaw & Co. — → Buy $15
2025-05-02 main Chardan Capital Buy → Buy $12
2024-12-04 main Chardan Capital Buy → Buy $12
2024-12-02 main Chardan Capital Buy → Buy $10
2023-08-15 reit Chardan Capital Buy → Buy $6
2023-05-11 main Chardan Capital Buy → Buy $6
2023-03-24 main Morgan Stanley — → Equal-Weight $2
2023-03-23 main Chardan Capital — → Buy $7
2023-01-30 main Chardan Capital — → Buy $8
2023-01-27 main Morgan Stanley — → Equal-Weight $3
2022-12-16 init JP Morgan — → Neutral —
2022-10-07 init Morgan Stanley — → Equal-Weight $8
2022-09-29 init B of A Securities — → Buy $7
2022-09-23 init Chardan Capital — → Buy $12
News
RSS: Latest SNTI news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-03-10 NEW ENTERPRISE ASSOCIATES 15, L.P. Beneficial Owner of more than 10% of a Class of Security — 3,333,000 — —
2025-03-10 RAJANGAM KANYA President — 33,000 $2.25 $74,250
2025-03-10 BAYER HEALTHCARE L.L.C. Beneficial Owner of more than 10% of a Class of Security — 2,222,000 — —
2025-03-10 CELADON PARTNERS SPV 24 Beneficial Owner of more than 10% of a Class of Security — 9,777,000 — —
2025-03-07 RAJANGAM KANYA President — 78,363 $0.00 $0
2025-03-07 LU TIMOTHY K M.D., PH.D. Chief Executive Officer — 642,358 $0.00 $0
2025-02-06 RAJANGAM KANYA President — 1,479 $4.07 $6,074
2025-02-06 LU TIMOTHY K M.D., PH.D. Chief Executive Officer — 4,467 $4.07 $18,339
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.02
0.00
-100.00%
1.98
-39.81%
3.29
Operating Revenue
0.02
0.00
-100.00%
1.98
-39.81%
3.29
Operating Expense
63.75
+4.98%
60.73
-11.66%
68.74
+5.16%
65.37
Research And Development
37.59
+9.40%
34.36
+6.86%
32.15
+14.23%
28.14
Selling General And Administration
23.43
-0.35%
23.51
-32.57%
34.87
-7.35%
37.63
General And Administrative Expense
23.43
-0.35%
23.51
-32.57%
34.87
-7.35%
37.63
Salaries And Wages
11.51
+37.40%
8.38
-63.75%
23.12
-15.97%
27.51
Other Gand A
11.91
-21.25%
15.13
+28.76%
11.75
+31.83%
8.91
Other Operating Expenses
—
—
-0.58
+41.70%
-1.00
Total Expenses
63.75
+4.98%
60.73
-11.66%
68.74
+5.16%
65.37
Operating Income
-63.73
-4.94%
-60.73
+9.05%
-66.77
-7.54%
-62.08
Total Operating Income As Reported
-68.78
-12.68%
-61.04
+34.17%
-92.73
-49.36%
-62.08
EBITDA
-60.09
-5.63%
-56.89
+7.25%
-61.34
-5.45%
-58.16
Normalized EBITDA
-55.04
-25.46%
-43.87
-10.95%
-39.54
+42.62%
-68.91
Reconciled Depreciation
3.64
-5.24%
3.84
-29.31%
5.43
+38.49%
3.92
EBIT
-63.73
-4.94%
-60.73
+9.05%
-66.77
-7.54%
-62.08
Total Unusual Items
-5.05
+61.19%
-13.02
+40.27%
-21.80
-302.74%
10.75
Total Unusual Items Excluding Goodwill
-5.05
+61.19%
-13.02
+40.27%
-21.80
-302.74%
10.75
Special Income Charges
-5.05
-1624.23%
-0.29
+98.86%
-25.75
-339.58%
10.75
Other Special Charges
—
—
—
-1.29
Impairment Of Capital Assets
5.05
+1514.06%
0.31
-98.79%
25.96
0.00
Restructuring And Mergern Acquisition
0.00
+100.00%
-0.02
+90.34%
-0.21
+97.81%
-9.46
Net Income
-61.44
-16.38%
-52.79
+25.71%
-71.06
-22.07%
-58.21
Pretax Income
-61.44
-16.38%
-52.79
+36.71%
-83.41
-67.94%
-49.66
Net Non Operating Interest Income Expense
0.93
-2.22%
0.95
-66.90%
2.86
+68.37%
1.70
Net Interest Income
0.93
-2.22%
0.95
-66.90%
2.86
+68.37%
1.70
Interest Income Non Operating
0.93
-2.22%
0.95
-66.90%
2.86
+68.37%
1.70
Interest Income
0.93
-2.22%
0.95
-66.90%
2.86
+68.37%
1.70
Other Income Expense
1.36
-80.51%
6.99
+135.83%
-19.50
-281.98%
10.72
Other Non Operating Income Expenses
6.41
-67.94%
20.01
+773.62%
2.29
+7256.25%
-0.03
Gain On Sale Of Security
—
-12.72
-421.34%
3.96
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-61.44
-16.38%
-52.79
+25.71%
-71.06
-22.07%
-58.21
Net Income From Continuing Operation Net Minority Interest
-61.44
-16.38%
-52.79
+36.71%
-83.41
-67.94%
-49.66
Net Income From Continuing And Discontinued Operation
-61.44
-16.38%
-52.79
+25.71%
-71.06
-22.07%
-58.21
Net Income Continuous Operations
-61.44
-16.38%
-52.79
+36.71%
-83.41
-67.94%
-49.66
Net Income Discontinuous Operations
—
0.00
-100.00%
12.35
+244.51%
-8.54
Normalized Income
-56.39
-41.77%
-39.77
+35.45%
-61.61
-1.98%
-60.41
Net Income Common Stockholders
-61.44
-16.38%
-52.79
+25.71%
-71.06
-22.07%
-58.21
Diluted EPS
-2.73
+77.31%
-12.03
+24.86%
-16.01
+28.21%
-22.30
Basic EPS
-2.73
+77.31%
-12.03
+24.86%
-16.01
+28.21%
-22.30
Basic Average Shares
22.48
+389.20%
4.60
+3.58%
4.44
+69.93%
2.61
Diluted Average Shares
22.48
+389.20%
4.60
+3.58%
4.44
+69.93%
2.61
Diluted NI Availto Com Stockholders
-61.44
-16.38%
-52.79
+25.71%
-71.06
-22.07%
-58.21
Depreciation Amortization Depletion Income Statement
2.73
-4.37%
2.86
+23.92%
2.31
+289.86%
0.59
Depreciation And Amortization In Income Statement
2.73
-4.37%
2.86
+23.92%
2.31
+289.86%
0.59
Insurance And Claims
—
—
1.66
+37.37%
1.21
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
51.22
-47.65%
97.84
-18.11%
119.48
-33.91%
180.79
Current Assets
23.27
-60.53%
58.96
-17.19%
71.20
-30.59%
102.58
Cash Cash Equivalents And Short Term Investments
16.42
-65.99%
48.28
+34.38%
35.93
-63.55%
98.56
Cash And Cash Equivalents
16.42
-65.99%
48.28
+34.38%
35.93
-37.65%
57.62
Cash Equivalents
—
35.87
+13.08%
31.72
—
Cash Financial
—
12.41
+195.08%
4.21
—
Other Short Term Investments
—
—
0.00
-100.00%
40.94
Receivables
1.59
-11.63%
1.80
-89.80%
17.70
+2728.12%
0.63
Accounts Receivable
0.32
+103.14%
0.16
+41.96%
0.11
-82.11%
0.63
Prepaid Assets
5.26
-36.60%
8.29
-52.26%
17.38
+464.12%
3.08
Current Deferred Assets
—
—
—
0.00
Assets Held For Sale Current
—
—
0.00
-100.00%
0.21
Other Current Assets
—
0.58
+199.49%
0.20
+93.07%
0.10
Total Non Current Assets
27.95
-28.11%
38.88
-19.48%
48.28
-38.27%
78.21
Net PPE
24.40
-30.75%
35.24
-15.32%
41.61
-40.37%
69.78
Gross PPE
37.46
-16.36%
44.79
-6.29%
47.79
-34.29%
72.73
Accumulated Depreciation
-13.06
-36.71%
-9.55
-54.50%
-6.18
-109.20%
-2.96
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.63
+0.00%
0.63
-8.16%
0.69
-2.00%
0.70
Construction In Progress
—
—
0.00
-100.00%
43.89
Other Properties
19.08
-11.24%
21.50
-12.11%
24.46
-6.90%
26.27
Leases
17.75
-21.68%
22.66
+0.05%
22.65
+1111.77%
1.87
Non Current Accounts Receivable
—
—
2.94
—
Other Non Current Assets
3.55
-2.64%
3.64
-2.52%
3.74
-55.69%
8.43
Total Liabilities Net Minority Interest
45.63
-36.79%
72.19
+37.32%
52.57
-1.79%
53.53
Current Liabilities
13.97
+6.30%
13.15
+3.74%
12.67
-29.81%
18.05
Payables And Accrued Expenses
5.86
+20.46%
4.86
+1.04%
4.81
-60.66%
12.24
Payables
2.94
+102.41%
1.45
+16.32%
1.25
-8.76%
1.37
Accounts Payable
2.94
+102.41%
1.45
+16.32%
1.25
-8.76%
1.37
Current Accrued Expenses
2.92
-14.49%
3.41
-4.32%
3.56
-67.20%
10.87
Pensionand Other Post Retirement Benefit Plans Current
2.37
-6.96%
2.54
+7.58%
2.36
+38.27%
1.71
Current Debt And Capital Lease Obligation
5.33
+14.70%
4.65
+12.57%
4.13
+107.65%
1.99
Current Capital Lease Obligation
5.33
+14.70%
4.65
+12.57%
4.13
+107.65%
1.99
Current Deferred Liabilities
0.35
-47.42%
0.66
-33.27%
0.99
+23.78%
0.80
Current Deferred Revenue
0.35
-47.42%
0.66
-33.27%
0.99
+23.78%
0.80
Other Current Liabilities
0.07
-83.14%
0.43
+14.55%
0.38
-71.36%
1.32
Total Non Current Liabilities Net Minority Interest
31.66
-46.38%
59.05
+47.99%
39.90
+12.47%
35.48
Long Term Debt And Capital Lease Obligation
23.56
-18.45%
28.89
-13.86%
33.54
-4.46%
35.10
Long Term Capital Lease Obligation
23.56
-18.45%
28.89
-13.86%
33.54
-4.46%
35.10
Non Current Deferred Liabilities
7.95
+62.24%
4.90
—
0.00
Non Current Deferred Revenue
7.95
+62.24%
4.90
—
0.00
Other Non Current Liabilities
0.15
+0.00%
0.15
+645.00%
0.02
-91.19%
0.23
Preferred Securities Outside Stock Equity
0.00
-100.00%
25.11
0.00
0.00
Stockholders Equity
5.59
-78.21%
25.65
-61.67%
66.91
-47.42%
127.26
Common Stock Equity
5.59
-78.21%
25.65
-61.67%
66.91
-47.42%
127.26
Capital Stock
0.00
+200.00%
0.00
+0.00%
0.00
-75.00%
0.00
Common Stock
0.00
+200.00%
0.00
+0.00%
0.00
-75.00%
0.00
Preferred Stock
—
—
—
0.00
Share Issued
30.88
+539.45%
4.83
+5.67%
4.57
+3.72%
4.41
Ordinary Shares Number
30.88
+539.45%
4.83
+5.67%
4.57
+3.72%
4.41
Additional Paid In Capital
364.16
+12.82%
322.78
+3.70%
311.26
+3.56%
300.54
Retained Earnings
-358.57
-20.68%
-297.13
-21.60%
-244.34
-41.01%
-173.29
Gains Losses Not Affecting Retained Earnings
—
—
0.00
-100.00%
0.00
Other Equity Adjustments
—
—
—
0.00
Total Equity Gross Minority Interest
5.59
-78.21%
25.65
-61.67%
66.91
-47.42%
127.26
Total Capitalization
5.59
-78.21%
25.65
-61.67%
66.91
-47.42%
127.26
Working Capital
9.30
-79.70%
45.81
-21.72%
58.53
-30.76%
84.53
Invested Capital
5.59
-78.21%
25.65
-61.67%
66.91
-47.42%
127.26
Total Debt
28.89
-13.86%
33.54
-10.96%
37.67
+1.55%
37.09
Capital Lease Obligations
28.89
-13.86%
33.54
-10.96%
37.67
+1.55%
37.09
Net Tangible Assets
5.59
-78.21%
25.65
-61.67%
66.91
-47.42%
127.26
Tangible Book Value
5.59
-78.21%
25.65
-61.67%
66.91
-47.42%
127.26
Derivative Product Liabilities
—
0.00
-100.00%
6.34
+4243.15%
0.15
Duefrom Related Parties Current
1.27
-22.72%
1.65
-90.64%
17.59
0.00
Duefrom Related Parties Non Current
—
0.00
-100.00%
2.94
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-43.44
-4.94%
-41.40
+20.99%
-52.40
-50.15%
-34.90
Cash Flow From Continuing Operating Activities
-43.44
-4.94%
-41.40
+20.99%
-52.40
-50.15%
-34.90
Net Income From Continuing Operations
-61.44
-16.38%
-52.79
+25.71%
-71.06
-22.05%
-58.22
Depreciation Amortization Depletion
3.64
-5.24%
3.84
-29.31%
5.43
+38.49%
3.92
Depreciation
3.64
-5.24%
3.84
-29.31%
5.43
+38.49%
3.92
Depreciation And Amortization
3.64
-5.24%
3.84
-29.31%
5.43
+38.49%
3.92
Other Non Cash Items
0.04
-99.32%
5.75
+806.02%
-0.81
+91.53%
-9.61
Stock Based Compensation
5.71
+225.13%
1.75
-81.85%
9.67
-41.01%
16.39
Asset Impairment Charge
5.05
+1514.06%
0.31
-98.79%
25.96
+216250.00%
0.01
Operating Gains Losses
—
-6.33
+74.86%
-25.18
-1853.45%
-1.29
Gain Loss On Investment Securities
—
-6.33
-90.81%
-3.32
—
Change In Working Capital
3.56
-41.36%
6.07
+30.14%
4.67
-66.45%
13.90
Change In Receivables
0.21
+129.49%
-0.71
+23.36%
-0.93
-609.16%
-0.13
Changes In Account Receivables
-0.16
-248.94%
-0.05
-109.27%
0.51
+487.02%
-0.13
Change In Prepaid Assets
3.72
-58.04%
8.86
+84.71%
4.79
+468.20%
-1.30
Change In Payables And Accrued Expense
2.30
+1726.98%
0.13
-70.42%
0.43
-80.99%
2.24
Change In Accrued Expense
0.56
+183.31%
-0.67
-193.72%
0.72
-65.16%
2.06
Change In Payable
1.74
+118.70%
0.80
+374.83%
-0.29
-255.91%
0.19
Change In Account Payable
1.74
+118.70%
0.80
+374.83%
-0.29
-255.91%
0.19
Change In Other Working Capital
-0.31
+4.86%
-0.33
-199.09%
-0.11
+89.35%
-1.03
Change In Other Current Assets
2.29
+13.86%
2.01
—
—
Change In Other Current Liabilities
-4.65
-19.71%
-3.88
-902.07%
0.48
-96.57%
14.13
Investing Cash Flow
-0.18
-641.18%
0.03
-99.89%
30.08
+136.70%
-81.96
Cash Flow From Continuing Investing Activities
-0.18
-641.18%
0.03
-99.89%
30.08
+136.70%
-81.96
Net PPE Purchase And Sale
-0.18
-641.18%
0.03
+100.28%
-11.93
+71.16%
-41.37
Purchase Of PPE
-0.20
-653.85%
-0.03
+99.78%
-12.04
+70.90%
-41.37
Sale Of PPE
0.01
-80.00%
0.06
-42.86%
0.10
0.00
Capital Expenditure
-0.20
-653.85%
-0.03
+99.78%
-12.04
+70.90%
-41.37
Net Investment Purchase And Sale
—
0.00
-100.00%
42.01
+203.51%
-40.59
Purchase Of Investment
—
0.00
+100.00%
-17.99
+55.67%
-40.59
Sale Of Investment
—
0.00
-100.00%
60.00
0.00
Gain Loss On Sale Of Business
—
0.00
+100.00%
-21.86
0.00
Financing Cash Flow
11.76
-78.11%
53.73
+6797.30%
0.78
-99.34%
118.55
Cash Flow From Continuing Financing Activities
11.76
-78.11%
53.73
+6797.30%
0.78
-99.34%
118.55
Net Issuance Payments Of Debt
—
0.00
+100.00%
-0.11
-102.09%
5.17
Issuance Of Debt
—
—
0.00
-100.00%
5.17
Repayment Of Debt
—
0.00
+100.00%
-0.11
0.00
Long Term Debt Issuance
—
—
0.00
-100.00%
5.17
Long Term Debt Payments
—
0.00
+100.00%
-0.11
0.00
Net Long Term Debt Issuance
—
0.00
+100.00%
-0.11
-102.09%
5.17
Net Common Stock Issuance
0.00
-100.00%
49.06
+9481.84%
0.51
-29.67%
0.73
Proceeds From Stock Option Exercised
11.18
0.00
-100.00%
0.38
-44.20%
0.67
Net Other Financing Charges
0.58
-87.56%
4.67
—
111.98
Changes In Cash
-31.87
-357.68%
12.37
+157.42%
-21.54
-1369.99%
1.70
Beginning Cash Position
51.81
+31.35%
39.45
-35.32%
60.99
+2.86%
59.29
End Cash Position
19.95
-61.50%
51.81
+31.35%
39.45
-35.32%
60.99
Free Cash Flow
-43.64
-5.35%
-41.42
+35.71%
-64.43
+15.52%
-76.27
Amortization Of Securities
—
0.00
+100.00%
-1.07
-200.28%
-0.36
Common Stock Issuance
0.00
-100.00%
49.06
+9481.84%
0.51
-29.67%
0.73
Issuance Of Capital Stock
0.00
-100.00%
49.06
+9481.84%
0.51
-29.67%
0.73
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category